Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Ups Stake in Aerie Pharmaceuticals Inc (AERI)

In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Deerfield’s passive position amasses 1.42 million shares of the company, up from some 565,200 shares held as of the end of the first quarter of the year.

Aerie Pharmaceuticals

Among other investors that own shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) as of the end of March is Baker Bros. Advisors, led by Julian Baker and Felix Baker, which held almost 299,400 shares, according to their latest 13F filing. Joseph Edelman‘s Perceptive Advisors has reduced its exposure to the company by 30% during the first three months of the year, to 211,500 shares. On the other hand, Stuart Weisbrod‘s Iguana Healthcare Management has upped its stake by 87% to 210,000 shares.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a small cap clinical-stage pharmaceutical company, which is specialized on products for therapy for the treatment of glaucoma and other eye diseases.

Disclosure: none

Loading Comments...